Alice Melão, MSc,  —

Treatment with Adcirca (tadalafil) plus Opsumit (macitentan) can provide functional benefits and lessen symptoms in newly diagnosed patients with pulmonary arterial hypertension (PAH), results from a clinical trial show. The data will be discussed at the upcoming CHEST Annual Meeting 2019, to be held Oct. 19-23…

Respira Therapeutics has regained full worldwide research, development, and licensing rights over its inhaled medicine-device combination product, called RT234, for the treatment of pulmonary arterial hypertension (PAH). This follows the decision of its partner United Therapeutics to terminate the collaboration with Respira, which was established…

Pulmonary hypertension contributes to markedly poorer outcomes and doubles a risk of death in people with moderate-to-severe problems in the heart’s tricuspid valve, a condition known as tricuspid regurgitation, a study from Europe reports. The study, “Impact of pulmonary hypertension on outcome in patients with moderate or severe…

Oral treatment with rodatristat ethyl is safe and well-tolerated, according to results from two completed Phase 1 clinical studies in healthy volunteers. These positive results support advancing the investigational therapy into Phase 2 studies involving people with pulmonary arterial hypertension (PAH), the treatment’s developer says. The most recent…

An enzyme involved in DNA damage processes, called EYA3, contributes to structural changes in lung blood vessels and to the progression of pulmonary hypertension (PH), according to a study in patient-derived cells and in rats. These findings also suggest that blocking EYA3 could be an effective treatment for people…

Translate Bio is focusing its efforts on the development of new therapies targeting pulmonary diseases, including pulmonary arterial hypertension and cystic fibrosis, among others. In light of this, the company is discontinuing the development of its lead candidate MRT5201 for ornithine transcarbamylase deficiency — a metabolic…

A rise in the volume of red blood cells may help to identify people with chronic obstructive pulmonary disease who are at risk of also developing pulmonary hypertension, a study from China reports. It also may potentially serve as a a cost-effective biomarker for PH secondary…

Analysis of gas exhaled in differing positions, like sitting or laying flat, could be a noninvasive and simple alternative to right heart catheterization in evaluating and managing people with chronic thromboembolic pulmonary hypertension (CTEPH), a study suggests. The study, “Usefulness of ventilatory gas analysis for the non-invasive…

While physicians worldwide are conducting multi-parametric risk assessments to evaluate pulmonary arterial hypertension (PAH), they are not doing so to the extent recommended by current guidelines, results from an international survey show. The survey found that PAH evaluations in clinical practice were not performed to the levels recommended by…

Long-term use of Orenitram led to moderate but durable, and dose dependent, improvements in exercise capacity in pulmonary arterial hypertension (PAH) patients, results from an open-label extension trial show. These findings were reported in the study “Long term study of oral treprostinil to treat pulmonary arterial hypertension:…

Abbott’s CardioMEMS HF system — a wireless heart failure monitor — can be safely used to monitor blood flow (hemodynamics) changes and help predict the risk of heart failure in people with pulmonary arterial hypertension (PAH), results from a pilot trial show. Additional studies in larger…

A new generic version of Actelion’s Tracleer (bosentan) developed by Teva Pharmaceutical was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH). The decision was supported by evidence that the generic bosentan has similar biochemical properties to…